# ANALYTIC MEMO

**Two questions:** (1) How consistent is Frawley's 1983 sworn dioxin-knowledge account with his own
1960s documents? (2) What does the de minimis episode reveal about the relationship between his
industrial role and his regulatory-science advocacy?

*Grading as in the dossier. The honest headline twice over: **no proven inconsistency**, but the
documents that could test the two genuine soft spots are exactly the ones still **sealed or
un-digitized** — and the deeper story is not contradiction but a lifelong, sincere, and
self-interested project of using first-rate toxicology to forestall regulation.*

---

## Part 1 — The 1983 sworn account vs. the 1960s documentary record

### 1.1 What Frawley swore (565 F. Supp. 1263, from his deposition + answering affidavit)
1. His **first knowledge** of industrial 2,4,5-T health problems came in **February 1965**, when **Dow**
   told him of its chloracne problem; he **did not learn of Monsanto's 1949 Nitro chloracne** until then.
2. Hercules **never had a worker chloracne case from 1961 to 1970** (when it ceased production).
3. Hercules's 2,4,5-T was **essentially dioxin-free** — no measurable dioxin Jan 1966–May 1970 **except
   one Sept 1966 test at .1 ppm**.
4. The **3 July 1963 letter** he wrote to Dow's V.K. Rowe concerned a USDA (Dr. John Leary) request to
   test phenoxy herbicides, and its health-hazard items **"relate to 2,4-D, not to 2,4,5-T."**
5. Hercules learned of possible **teratogenicity** only in **1969**, via the government's Bionetics Report.

This account won Hercules summary judgment: the court reasoned that because the product "was free of the
contamination… [Hercules's] knowledge could not have exceeded that of the government."

### 1.2 Testing each claim against the contemporaneous record

| Sworn claim | Contemporaneous evidence we actually hold | Verdict |
|---|---|---|
| (1) First knowledge Feb 1965; March 1965 Dow meeting | **The 19 Mar 1965 Rowe→Frawley letter (Poison Papers B 1575) is CONFIRMED-primary and SUPPORTS the chronology** — it convenes the very meeting his affidavit describes. | **Consistent / corroborated** |
| (2) No knowledge of Monsanto 1949 before Feb 1965 | No document predating Feb 1965 in our set shows Hercules/Frawley aware of Nitro. *Absence is not proof*, but nothing contradicts it. | **Not contradicted** |
| (3) No worker chloracne 1961–70 | No contrary document located. Untestable from open sources (Hercules medical records not available). | **Untestable; uncontradicted** |
| (4) Product essentially dioxin-free (.1 ppm peak) | The court's figures trace to Hercules's own testing (per affidavit). The independent **1991 NIOSH Dioxin Registry** (not yet read) could corroborate or complicate. | **Self-sourced; independent check pending (D1)** |
| (5) The 1963 letter was about 2,4-D, not 2,4,5-T | **The ONLY characterization of Doc A's content is Frawley's own affidavit.** The primary letter is **not digitized**; plaintiffs read it the opposite way. **Cannot be independently verified.** | **Unresolvable on current evidence** |

### 1.3 The two genuine soft spots — and why they stay open
- **Doc A (claim 5).** This is the cleanest potential inconsistency, and it is structurally
  un-adjudicable from open sources: the document exists, but the *only* available reading of it is the
  affiant's. A letter from Hercules's toxicologist to **Dow's chief toxicologist** about phenoxy-herbicide
  testing **in 1963** at minimum establishes a Hercules–Dow scientific channel **18 months before** the
  sworn "first knowledge" date — though on Frawley's telling that channel concerned 2,4-D, not the
  2,4,5-T/dioxin problem. **To resolve: obtain the scan (NARA MDL 381 exhibits or Dow's files).**
- **Doc B (the 1965 "extremely frightened" memo).** If its wording is accurate, it shows that **by 1965
  Frawley contemporaneously recorded** that (a) a Dow study found dioxin caused **severe liver damage in
  rabbits**, and (b) Dow feared "**the whole industry will suffer**" if the government found out. This is
  **not strictly inconsistent** with the sworn account — Frawley dated his first dioxin knowledge to exactly
  this period (Feb–Mar 1965), and one can simultaneously know "dioxin is dangerous" and believe "*our*
  product is clean." **But it reframes the legal victory:** the SJ narrative ("Hercules had no knowledge
  of its product creating hazards to people") sits beside a documentary picture of Frawley as a knowing
  participant in an industry that was **actively keeping dioxin's hazards from regulators**. The memo is
  **real** — NYT reporters quoted it in 1983 from the documents Judge Pratt unsealed — but its exact
  wording now reaches us only through a chain of secondary paraphrase, and **no public exhibit/Bates
  number or scan exists.** **To resolve: the 1983 NYT articles (TimesMachine) and NARA MDL 381.**

### 1.4 Bottom line on consistency
**There is no demonstrated lie.** Frawley's sworn chronology is internally coherent and is *corroborated*
by the single fully-verified contemporaneous document we hold (the March 1965 Rowe letter). The legal
account is best described as **narrowly true and broadly incomplete**: true that Hercules's *own product*
was unusually clean and that its formal "first knowledge" came in 1965; incomplete in that the same 1965
moment placed Frawley inside a documented, deliberate industry effort to keep dioxin's toxicity from the
government — a context the government-contractor defense did not require him to volunteer, and which the
sealing order (PTO 43) kept out of public view until the 1983 unsealing. **The decisive tests are
gated behind sealed/un-digitized primaries (Doc A scan, Doc B exhibit, the full deposition).**

---

## Part 2 — The de minimis episode and the industrial-role / regulatory-advocacy relationship

### 2.1 The pattern, stated plainly
The de minimis proposal is the clearest specimen of a method that recurs across Frawley's career:
**marshal genuine, competent toxicology to argue that the chemistry his employer sells does not warrant
regulation — and do so from the credibility of a former FDA insider, without disclosing the alignment
between the conclusion and the payer.**

- **The driver was commercial and explicit.** His own 1965 rosin paper lays it out: the 1958 amendment
  forced 2-year studies on Hercules's food-grade rosins; **34 products × ~$50,000** was the bill; the
  studies were farmed to **IBT**. The 1967 proposal would have **deleted ~75% of the citations** in the
  U.S. food-packaging regulations — i.e., deregulated exactly this chemistry. **[CONFIRMED-primary]**.
  *And he said the quiet part out loud, to FDA's face:* at the **13 Feb 1968 National Conference** he told
  the room **"I personally had spent over a million dollars of my Corporation's money investigating the
  safety of food packaging materials… it was all wasted, because all were proven to be safe"** — the
  sunk-cost grievance, in the first person, is the engine of the whole "toxicologically insignificant"
  case. **[CONFIRMED-primary]** (FDCLJ 23:261, local PDF).
- **The "consensus" was a campaign.** The same 1968 address advertises that **"twenty-four other
  toxicologists… supported this proposal in writing to the FDA"** and that lawyers had told him this alone
  made the uses "gras." Read against `08_VINYL_CHLORIDE_CAMPAIGN.md`, this public "24 letters" tally is the
  visible tip of the **coordinated SPI / Allied Signal indirect-additives campaign** — i.e. the
  "overwhelming professional support" was, in part, an organized industry lobbying effort presented as
  spontaneous scientific consensus. **[CONFIRMED-primary]** (the claim) + **[secondary→primary]** (the
  campaign behind it, from the SPI files).
- **The evidence base was partly his own employer's and his own contractor's.** The 1967 paper's
  220-compound appendix rests in part on unpublished **Hercules** (ref. 3, 3 compounds) and **IBT** (ref. 26,
  4 compounds) data. IBT is the lab whose late-1970s **data-fraud** conviction (*United States v. Keplinger
  et al.*) voided a generation of pesticide/additive safety studies; Frawley's multigeneration-reproduction
  papers with IBT's president **J. C. Calandra** (1963, 1965, 1973) are the very *genre* later found fraudulent.
  **[CONFIRMED-primary]**. **Now cross-referenced against the EPA IBT audit (full analysis in
  `09_IBT_FRAWLEY_OVERLAP.md`):** Frawley's *explicit* IBT reliance is only **4 D&C colour additives**, disjoint
  from EPA's pesticides-only review. ~14 of his pesticides are IBT-reviewed chemicals, but he cited them to
  **Lehman** — and the "Lehman just launders IBT" worry is **structurally foreclosed**: Lehman = the FDA Division
  of Pharmacology's own pre-1955 in-house data (several values authored by **Frawley himself** at FDA — e.g.
  parathion = Frawley & Fuyat 1957), and the IBT studies on those compounds post-date him (1967+). The real IBT
  vein is the tight **Hercules↔IBT** channel — Calandra co-authorships, the EPA-invalidated **Hercules toxaphene**
  study, the "BFC"/Hercules agrochemical cluster — which enters via his **own** ref-3/ref-26, not Lehman. So the
  linkage is **documented (one chain), bounded, and NOT** a finding that his published dataset rests on the
  invalidated studies. **Separately**, hindsight shows many of his "no-effect levels" failed
  outright (vinyl chloride 120,000 ppm, acrylamide, the azo dyes → genotoxic/no-threshold; cyclamate banned 1969) —
  a *method* failure independent of IBT (`09` §7).
- **The COI was not disclosed as such.** Beyond his Hercules by-line, no contemporary source flags the
  conflict; the NAS committee that reviewed the idea had Frawley **on it** (he declined to draft the
  report — UCSF yhgd0228). **[CONFIRMED-primary]** that the interest existed; **[absence-of-evidence]**
  that anyone named it.

### 2.2 Why this is not simply cynicism
The honest reading is **sincere conviction fused with interest**, not fraud. Frawley genuinely believed —
and argued in the same "common sense" register for 25 years ("Our sacred food," 1965 and again 1989) —
that most food-packaging regulation was scientifically unjustified relative to its public-health return.
His science was real: the 1967 database showed that essentially all non-pesticide, non-heavy-metal
compounds were safe at 0.1 ppm, an observation **Rulis (FDA, 1987) independently re-derived and credited
to him**, and which is now embedded in FDA's 1995 Threshold of Regulation rule and the international TTC.
**The de minimis idea was right enough to outlive its conflicted origin.** That is precisely what makes
the episode instructive: the same intellectual move that produced a durable regulatory-science advance
also happened to deregulate his employer's products, rested on his employer's and IBT's unpublished data,
and was advanced without disclosure — a textbook "product-defense"/threshold maneuver of the kind later
anatomized by Michaels, Markowitz & Rosner, and Oreskes & Conway.

### 2.3 The 1981 manifesto — and the GLP / IBT irony *(from the newly-added primary)*
Frawley's inaugural *Regulatory Toxicology and Pharmacology* article, **"The 1980s — A Decade of
Change"** (1(1):3–7; delivered to the **International Academy of Environmental Safety**, Williamsburg,
June 1980), is his ideological self-portrait. He attacks the **"zero risk" / Delaney philosophy** as the
cause of a "disastrous" shift from government–industry "mutual respect" to "distrust," blames "individuals
untrained in the scientific process, especially lawyers," dismisses statistical cancer-risk extrapolation
as "the fad of the eighties" and "a device for regulators to communicate to the public in a reassuring
manner," and defends the older "safe beyond a reasonable doubt" standard — conceding toxicologists were
once "somewhat cavalier" about tumors at the maximum tolerated dose.

The remarkable passage is his attack on **Good Laboratory Practices (GLPs)** — "the most onerous
development of the seventies" — which, he complains, "merely refer to proof that there was no cheating in
the experiment," lamenting the lost world where data were trusted "scientist to scientist" and protesting
that "a reputation, built on a career of integrity, is worth nothing today." **The irony is acute and
material to this dossier:** GLPs were promulgated by the FDA *specifically in response to the IBT
data-fraud scandal* — and **IBT is the very contract lab, run by Frawley's repeated co-author J. C.
Calandra, that performed Frawley's rosin studies and supplied data behind the de minimis appendix.**
In 1981 Frawley publicly defended the pre-GLP "mutual trust" regime at the exact moment that regime had
been shown — through a lab to which he was tied — to have been systematically abused. One need not infer
personal complicity (see the A6 caveat) to register that his deregulatory philosophy and his commercial/
contractual entanglements pointed the same direction. *(Full text: `papers/Frawley - 1981 …pdf`.)*

### 2.3b The ToxicDocs evidence — the de minimis proposal as an industry campaign *(decisive for this thesis)*
The 251 ToxicDocs documents (now mined locally; see `07_TOXICDOCS_FINDINGS`) move the industrial-role
thesis from *inference* to *documentation*. The vinyl-chloride/SPI cluster (1966–72) shows the
plastics- and chemical-industry coalition adopting Frawley's 0.2% proposal as its banner (the *"Frawley
proposal / doctrine / concept"*), with the **Manufacturing Chemists Association** (40 files), *Food
Chemical News*, and FDA all drawn in — Frawley **leading an industry delegation to FDA**, sitting on a
**"three-man" negotiating committee**, and **advising the MCA on the Delaney Clause**. The same files show
he was the industry's reassuring toxicologist across *unrelated* hazards too — the **1958 confidential
Monsanto letter** enclosing his Pydraul/Cellulube results, *"although Frawley doesn't consider the
materials as being particularly toxic."* His role and his employer's/industry's interest were not merely
*aligned*; the record shows him **operating the alignment** — drafting, lobbying, and negotiating the
self-exempting threshold. *(This is the strongest evidence in the dossier; it is also why the GLP passage
in §2.3 lands so sharply.)*

### 2.4 The throughline to the dioxin file
The two strands rhyme. In **food packaging** Frawley used toxicology to argue *down* the need for
regulation of Hercules products; in the **1965 dioxin episode** his contemporaneous memos record an
industry preoccupied with avoiding "restrictive legislation" and a "congressional investigation," and his
1983 affidavit then deployed Hercules's genuinely-clean dioxin numbers to win a liability dismissal. The
constant is the deployment of sophisticated, defensible science in the service of minimizing the chemical
industry's **regulatory and liability exposure** — sincerely argued, technically competent, and
financially aligned. The Arnold J. Lehman Award he received in 1987 — named for his own FDA mentor, for
"applying sound scientific principles to regulation" — is the establishment's recognition of exactly this
career, and a neat emblem of how thin the line was, in mid-century regulatory toxicology, between
public-health science and industrial advocacy.

---

## Confidence statement
- **Highest confidence:** the de minimis chronology and FDA reaction (Strand I); Frawley's centrality to
  the Agent Orange SJ and the verbatim affidavit content (cross-confirmed across 3 agents); the 19 Mar
  1965 Rowe→Frawley primary; the IBT/Hercules COI; the congressional negative.
- **Medium:** Doc B's exact wording (secondary chain to 1983 NYT) and its "real but un-cited" status; the
  death-date bracket.
- **Open / do not over-claim:** the 1953 MASH identity; whether Doc A genuinely concerned only 2,4-D;
  whether any pre-1965 Hercules dioxin knowledge exists in the sealed record.

---

## Part 3 — Adversarial verification of the five highest-stakes claims

Five independent skeptics were each told to *try to refute* one claim using fresh primary searches.

| # | Claim tested | Verdict | What the skeptic found |
|---|---|---|---|
| 1 | 1983 sworn account is **consistent** with the 1960s documents | **PARTIALLY-SUPPORTED** | Consistent *where testable* — the March 1965 Rowe→Frawley primary falls inside his named first-knowledge window and corroborates it; the six opinion sentences re-confirmed verbatim. **Not testable** for the one document the claim names first (the 1963 letter — never digitized, only self-characterized, read oppositely by plaintiffs). |
| 2 | Frawley **never testified before Congress** (Goddard, not Frawley, at Dingell 1967) | **SUPPORTED** | Dingell-1967 = Goddard confirmed (Heckman + Daily Digest). The strongest refutation lead — UCSF tobacco docs titled *"Statement of John P. Frawley, Ph.D. Before the [House] Subcommittee on Health and the Environment"* (1994) — was run down: the **complete printed record of the 1994 Waxman tobacco hearings (all 3 vols, 7 dates) contains zero "Frawley."** The statement was a **DRAFT prepared by/for the tobacco industry (Covington & Burling), never delivered.** |
| 3 | Death ≈ 2003–2004, resting only on the SOT asterisk; **no obituary found** | **PARTIALLY-SUPPORTED** | No genuine obituary or death record exists online (the only dated "John P. Frawley" obit — d. 2007, NJ pipe-fitter b. 1946 — is a clear impostor). The asterisk bracket holds; "2002–2004" is better stated **~2003–2004**. |
| 4 | Document B is a **genuine primary established by a traceable exhibit/Bates handle** | **REFUTED** | The wording traces to a **single uncited popular narrative** ("The Story of Agent Orange"); **no footnote, Bates, exhibit, or case is cited anywhere.** The underlying memo may be genuine (the 1983 press saw it) but the *traceable-handle* part of the claim fails. |
| 5 | Frawley was **not** a witness/affiant in the EPA FIFRA 2,4,5-T proceedings | **PARTIALLY-SUPPORTED** | Supported by absence-of-evidence: every Frawley dioxin statement traces to the *private tort* MDL, not the FIFRA cancellation docket (where Dow's Rowe testified). Caveat: the FIFRA sub-dockets (295/409/410/415/438) are not exhaustively indexed online. |

**Net effect on the memo:** Part 1's "no proven inconsistency, decisive tests gated behind sealed
primaries" survives adversarial testing intact (verdict 1). The Document B refutation (verdict 4)
hardens §1.3's caution. And verdict 2 surfaced the single most important *new* biographical fact in
the whole investigation — see Part 4.

## Part 4 — The product-defense arc, completed: Frawley and Big Tobacco (new)

Verdict 2's adversarial dig produced a finding none of the reconnaissance agents had nailed down:
**in his last active years Frawley worked as a paid expert for the tobacco industry.** In March–April
**1994** a **"Statement of John P. Frawley, Ph.D."** was drafted for submission to the House Subcommittee
on Health and the Environment (the Waxman tobacco hearings). UCSF Industry Documents Library metadata
ties it unambiguously to *our* Frawley — *"FRAWLEY JP # HEALTH & ENVIRONMENT INTERNATIONAL LTD,"* Hercules,
Society of Toxicology, Academy of Toxicological Sciences, ex-FDA — and the documents sit in the **Tobacco
Institute** and **RJR** legal files, marked **DRAFT** with **Covington & Burling** privilege-log
boilerplate ("in anticipation of litigation"). The statement was **never delivered or entered into the
record.**

This is the throughline's natural endpoint. A career that began inside the FDA's Division of Pharmacology,
moved to defending Hercules's rosins (de minimis) and Hercules's Agent Orange (the dioxin affidavit),
and ran a consultancy named **Health & Environment International Ltd.**, closes with the toxicologist
being enlisted — through the tobacco industry's outside counsel — to help blunt tobacco regulation. The
same instrument throughout: credentialed, technically competent toxicology, deployed to argue that the
product in question does not warrant the regulation proposed for it. That the 1994 statement was a
litigation-driven draft that never reached the public record is itself emblematic of the genre.

*(Document IDs for the 1994 statement: UCSF IDL **zqxb0104**, **lhyg0018**, **hmkb0121**, **tjhg0001**,
**xhyn0050**. See `03_DOCUMENT_REGISTER` and `05_OPEN_QUESTIONS` A5.)*

---

## Part 5 — The numerology lineage: the heirs of the round number *(lateral research, 2026-06-11)*

*Frawley's de minimis is one specimen of a wider pattern the series is really about: **a round number used
as a stand-in for knowledge we don't have.** Five adjacent threads — each now backed by held primaries
(register **H1–H10**) — show the same device before, around, and after him. They feed the essay (candidate
block in `reckoningscience/`); they are catalogued here so the analysis lives in one place. The discipline
throughout: the **10⁻⁶ keystone is fully primary-confirmed locally**; the rest is graded honestly, and the
Frawley↔Ames tie is framed as **parallelism, not influence** — no direct citation between them was found.*

### 5.1 The keystone — 10⁻⁶, the carcinogen-side de minimis (THE missing twin)
The essay's §9 names a void: for a genotoxic carcinogen no dose does nothing, so the "no-effect level" his
table is built on **does not exist** for them. Regulators did not stop at that wall — they built a threshold
anyway, out of a different round number: a lifetime cancer risk of **one in a million (10⁻⁶)**. It is Frawley's
exact move performed on the one class of chemicals that has no threshold. The full reconstruction (DES Proviso
→ Hutt's redefinition of "no residue" as a calculated 10⁻⁶ dose → the 1995 rule's 0.5 ppb being *itself* a
10⁻⁶ calculation off a 477-carcinogen bell curve) is in **`10` §3.5/§4**. Two facts are decisive and **local
primary**: (a) Rodricks (firsthand) records Hutt choosing "**less than 1 in 1 million**" on a no-threshold
model, two orders up from Mantel's already-arbitrary 10⁻⁸ "virtually safe dose"; (b) the 1995 FR, in its own
voice, derives 0.5 ppb as a sub-one-in-a-million risk and waves off the factor-of-100 echo as "**merely
coincidental**." **[CONFIRMED-primary]** (H1; 60 FR local). The derivation behind 0.5 ppb — the **477-carcinogen
potency bell curve** — is now held primary too (Rulis 1992, **H13**, "Ref. 1" of the rule). **And the law where
10⁻⁶ actually lives is now held and read in full — the SOM final rule, 52 FR 49572 (1987), register H25** — which
clinches the reading in the agency's own words: it defines the permitted residue as the dose at "a maximum
lifetime risk of cancer to the test animal on the order of **1 in 1 million**," reached via an "**operational
definition of 'no residue'**" that FDA **expressly distinguishes from the de minimis doctrine**; records 10⁻⁶ as
an adopted **consensus** (commenters said 10⁻⁵ or 10⁻⁴ "might also" be insignificant); and concedes the number
must be "**high enough to permit the use of carcinogenic animal drugs**" — i.e. chosen to be both small enough
to call safe and large enough to keep the product legal. Lowe 1989 (**H27**) is the same argument from inside
FDA, in the open literature, the year Frawley reprised "Our sacred food." **And the number's whole trajectory is
now on the contemporaneous rulemaking record (H32, the earlier SOM stages):** the **1973 proposal** set it at
Mantel's **10⁻⁸**, calling it "an arbitrary but conservative level"; the **1977 final rule moved it up to "1 in 1
million"**; the **1979 reproposal §8** defended the move — 10⁻⁸ was "unduly limiting without substantial
compensation in terms of public health," the criterion being to "be as high as possible in order to permit the
use of carcinogenic animal drugs." So Rodricks's Hutt account is corroborated **and dated**: the number was
chosen — between round numbers ("difficult to choose between 1 in 1 million and 1 in 10,000") — not derived.
The number's own
users could not document its origin when surveyed: **Kelly 1991 (now held & read firsthand, H12)** found 10⁻⁶
has "no scientific or regulatory basis," and collected the officials' confessions ("sounded like such a nice
phrase"; "doable"; "You really shouldn't be asking these questions") — **[secondary]** for the survey's claims;
the Mantel "we just pulled it out of a hat" line is anecdotal (Kelly the source), **not** primary. And the number
isn't even what agencies *apply*: **Travis et al. 1987 (now held, H24)** reviewed **132 federal regulatory
decisions** and found the *de facto* "acceptable risk" tracked **nearer 10⁻⁴ and moved with the size of the
exposed population** — political, not toxicological — while itself reciting "**de minimis non curat lex.**"
**[CONFIRMED-primary]** (H24). So 10⁻⁶ is a round number with no documented origin (Kelly), no scientific basis
(Kelly), and no consistent application (Travis) — the carcinogen-side twin of Frawley's 0.1 ppm.

**The indirect root (operator query, 2026-06-11) — now primary end to end (2026-06-13):** the held histories
trace the 10⁻⁶ method's ancestry to the **Lehman–Fitzhugh safety-factor (factor-of-100) approach (1949–55)** it
was built to replace — *the first essay's number, run by Frawley's own FDA mentors* — with the no-threshold
premise imported from **radiation carcinogenesis**. That import is no longer a [P-cite]: the radiation primaries
are now held and read. **Lea 1946 (H31)** lays down the **single-hit target theory** — gene mutation "due to a
single ionization," hence an exponential, threshold-free dose-effect (Mantel & Bryan cite Lea, their ref 12).
**NBS Handbook 59 / NCRP-17 (1954, H29)** drew the policy consequence first, in radiation protection: "**there is
no threshold dose for the production of gene mutations… no such thing as a tolerance dose**," so it retired
"tolerance dose" for a "**permissible dose**" set by "**readily acceptable**" risk — the headwater of "acceptable
risk." **Crump, Hoel, Langley & Peto 1976 (H26)** carried the single-hit logic into chemical carcinogenesis
(linear-at-low-dose "under almost any model") and named the lineage — linear extrapolation "**as it was for
radiation 20 years ago**" — while conceding in footnote 3 that 10⁻⁶ vs 10⁻⁸ has "**no compelling reason**." So
Frawley's 0.1 ppm and the carcinogen 10⁻⁶ are **two branches off one Lehman–Fitzhugh trunk**, and the 10⁻⁶
branch's no-threshold premise is itself **transplanted from 1954 radiation protection**, where "acceptable risk"
replaced "safe dose." **[CONFIRMED-primary]** (Rodricks H1 / Crump H2; Lea H31 / NBS-59 H29 / Crump-1976 H26;
see `10` §3.5 and the batch-2 excerpts in `sources/`).

### 5.2 Bruce Ames — the trifle scaled to the whole diet
Maximum irony, and a clean coda. Ames **built the no-threshold screen** (the *Ames test*, 1973 — the assay
that says a genotoxin has no safe dose), then a decade later became the apostle of "it's all trivial":
**"99.99% (by weight) of the pesticides in the American diet are … natural,"** synthetic residues
"insignificant" (*PNAS* 1990). Frawley said *this additive* is a trifle; Ames said the *entire diet* is — de
minimis at cosmic scale, in a new round number (99.99%). The earlier **HERP table** (Human Exposure/Rodent
Potency — peanut-butter sandwich and wine outranking synthetic residues) is now held too: **Ames, Magaw & Gold,
*Science* 236:271 (1987), H14**. The NAS lent its name **again** — **NRC 1996, *Carcinogens and Anticarcinogens in
the Human Diet* (now held & read, H30)** — but with a precise limit worth keeping: the Academy granted Ames's
**mechanistic** premise ("**no notable mechanistic difference… no clear difference between the potency of known
naturally occurring and synthetic carcinogens**," 200+ agents, 65 natural; "evaluated by the same… methods") yet
**declined the de minimis conclusion**, calling the risk "implications… controversial" and flagging "numerous
and extensive gaps." So the NAS "same yardstick" is the 1969-Guidelines move repeated three decades on — but this
time the Academy blessed the *yardstick*, not the *trifle*. **All four Ames primaries [CONFIRMED-primary]** (H3–H5,
H14), and the NAS endorsement is now primary too (H30).
**Caveat held for fairness:** the HERP ranking conflates exposure-ranking with risk — **Perera & Boffetta 1988
(now held, H20)**, the principal HERP critique, "analyzed the assumptions and data set upon which the HERPs were
based" and found exactly that; Ames's own "too many rodent carcinogens" cuts both ways. **Connective tissue, not influence:**
Frawley published in the **inaugural June 1981 *Regulatory Toxicology and Pharmacology*** — the ISRTP "sound
science" venue where Ames's argument lived — but **no Frawley↔Ames citation was found.** Frame as parallel
apostles of one logic in one milieu. (Confirming the Vol. 1 No. 1 TOC would flip the milieu link to primary —
`05` §C7.)

### 5.3 The RfD / uncertainty-factor tower — the factor of 100, metastasized (bridge to essay one)
EPA's **Reference Dose** is the first essay's factor of 100 grown into an official tower: a NOAEL divided by a
*product* of round tens (×10 interspecies × ×10 intraspecies = 100; +×10 subchronic→chronic; +×10 LOAEL→NOAEL;
+×10 database → divisors of 1,000 and 10,000). EPA's 2002 process review carries the structure and the
admission that the RfD is an estimate good to "an order of magnitude" — **[CONFIRMED-primary]** (H6). The
RfD-history paper **Dourson & Stara (1983, now held, H18)** traces the practice explicitly to **Lehman & Fitzhugh
(1954, held, H16)** — *the same editorial the first essay is built on.* **The two RfD-history papers say
different things — both now held and quotable (the misattribution is resolved):**
- **Barnes & Dourson (1988, H21)** *concedes the origin*: "**the original selection of SFs appears to have been
  rather arbitrary**" (the "rather arbitrary" wording belongs here, **not** to the 1983 paper — quote it to
  Barnes & Dourson 1988).
- **Dourson & Stara (1983, H18)** *defends the present use*: the factors "**are not arbitrary as is commonly
  perceived**" — an attempt to give the round tens retroactive experimental support. The tell is that the
  defense was needed because the factors are "commonly perceived" as arbitrary.
The pair is the perfect specimen: the field both **admits the number was picked arbitrarily** and **argues it
has since earned its keep.** **[CONFIRMED-primary]** (H16, H18, H21).
**The judgment-vs-statistics axis (new primary):** **Weil (1972, held, H17)** is the other pole — he "deprecates"
statistical low-dose extrapolation and recommends instead "a suitably large safety factor, e.g., **1/5000 of the
lowest-effect dose level for cancer**," set by "properly informed, **scientific judgment**." Weil is the
safety-factor camp (Lehman-Fitzhugh's heirs) arguing *judgment over statistics* — the same stance Frawley took
in his 1981 manifesto (§2.3), and another appointed round number (1/5000). So the factor-of-100 lineage runs
**Lehman-Fitzhugh 1954 → Weil 1972 (judgment) / Mantel-Bryan 1961 (statistics) → Dourson-Stara 1983 (the RfD
defense) → EPA RfD tower.** **[CONFIRMED-primary]** (H6, H16, H17, H18).

### 5.4 GRAS self-certification — naming the machine Frawley was working (sharpens, adds no new fact)
The dossier already had the quote; it never named the mechanism. At the Feb 1968 conference Frawley said lawyers
told him that two dozen experts writing in "confirms that these uses are generally recognized as safe or 'gras'
and that no action on the part of the FDA is necessary" (`papers/fdclj_1968.txt`) — **[CONFIRMED-primary]**. So
his "24 toxicologists in writing" was not a plea for a rule; it was a **GRAS self-certification** — manufacture
the expert consensus, declare it safe, skip the test — invoking the off-ramp created by the **same 1958
amendment** he was trying to escape (FFDCA §201(s)). The modern endpoint makes the COI rhyme exact: companies
self-determine GRAS **"without FDA's approval or knowledge"** (GAO-10-246, **[CONFIRMED-primary]**, H7),
notification stayed **voluntary** through 2016 (81 FR 54960, H8), and an NGO count found 275 chemicals on
undisclosed GRAS (NRDC 2014, **[secondary]**, H9). The sharp COI percentages — of **451** GRAS notifications,
**22.4%** assessed by a manufacturer employee, **13.3%** by a manufacturer-selected consulting firm, **64.3%** by
a manufacturer/firm-selected expert panel, **0%** by an independent party — are now held: **Neltner et al.,
*JAMA Intern. Med.* 173(22):2032 (2013), [CONFIRMED-primary], H15.** **Anachronism guard:** in 1968 the voluntary-notification
regime did not yet exist — Frawley invoked the GRAS **concept**; say "concept." This folds into §2.1/§2.3b above
and the essay's §3/§4 and §6; **not a new section.**

### 5.5 TLVs / Castleman–Ziem — the occupational mirror (rhymes with vinyl chloride)
ACGIH's **Threshold Limit Values** (first published 1950) are the occupational round numbers. **Castleman &
Ziem (1988, now held, H22)** found, verbatim: "**Unpublished corporate communications were important in
developing TLVs for 104 substances; for 15 of these**," that was the sole basis — company "consultants" writing
the TLVs for their own employers' chemicals: the same move as de minimis (industry sets the "safe" number; it
becomes the standard). And **Roach & Rappaport (1990, now held, H23)** — "**But They Are Not Thresholds**" —
found the TLV documentation does not actually support the "threshold" claim the values assert: the round number
again outruns the science. Connects to §9's vinyl chloride, which had a comfortable TLV before it had a cancer
finding. **[CONFIRMED-primary]** (H22, H23).

### 5.6 Net effect on the dossier's thesis
Part 2 argued Frawley's de minimis was *sincere conviction fused with interest*, and a recurring **method**.
Part 5 shows that **method is not idiosyncratic to him** — it is the native grammar of mid-century-to-modern
regulatory toxicology: when the science can't supply a threshold, a round number is appointed to stand in
(0.1 ppm; 10⁻⁶; ×100; 99.99%; a TLV), and an authoritative body (NAS, FDA, EPA, ACGIH) ratifies it. The 10⁻⁶
thread is the strongest addition because it fills the exact gap the essay opens and never closes: **where a
no-effect level cannot exist, regulators built one anyway, and its own authors say it has no scientific basis.**